The Hill News

The Small Business Innovation Research (SBIR) grant program has fostered the growth of fledgling companies during some of the most challenging times in their business cycles, and supported the advancement of important products to the marketplace, including transformational biomedical therapies that can improve the lives of children and adults suffering from genetic disorders, infectious diseases, cancer and autoimmune diseases. 

Sadly, current rules resulting from a 2003 Office of Hearings and Appeals decision have inhibited and interfered with the growth and survival of small private biotechnology companies and the development of promising technologies and products due to the inability of venture-backed companies to participate in the SBIR program.

Read more...